Demographic and Clinical Factors Associated With SARS-CoV-2 Anti-Nucleocapsid Antibody Response Among Previously Infected US Adults: The C4R Study - Takeaways - MDSpire

Demographic and Clinical Factors Associated With SARS-CoV-2 Anti-Nucleocapsid Antibody Response Among Previously Infected US Adults: The C4R Study

  • By

  • Ryan T Demmer

  • Chaoqi Wu

  • John S Kim

  • Yifei Sun

  • Pallavi Balte

  • Mary Cushman

  • Rebekah Boyle

  • Russell P Tracy

  • Linda M Styer

  • Taison D Bell

  • Michaela R Anderson

  • Norrina B Allen

  • Pamela J Schreiner

  • Russell Bowler

  • David A Schwartz

  • Joyce S Lee

  • Vanessa Xanthakis

  • Jean M Rock

  • Rachel Bievenue

  • Amber Pirzada

  • Margaret Doyle

  • Elizabeth A Regan

  • Barry J Make

  • Alka M Kanaya

  • Namratha R Kandula

  • Sally E Wenzel

  • Josef Coresh

  • Carmen R Isasi

  • Laura M Raffield

  • Mitchell S V Elkind

  • Virginia J Howard

  • Victor E Ortega

  • Prescott Woodruff

  • Shelley A Cole

  • Joel M Henderson

  • Nicholas J Mantis

  • Elizabeth C Oelsner

  • March 20, 2025

  • 0 min

Share

  • 1

    COVID-19 remains a leading cause of death, highlighting the need for effective identification of high-risk individuals.

  • 2

    The study analyzed anti-nucleocapsid antibody responses in 1419 adults with prior SARS-CoV-2 infection from diverse backgrounds.

  • 3

    Anti-nucleocapsid antibody reactivity peaked at 69% four months post-infection but declined to 44% after twelve months.

  • 4

    Higher antibody responses were linked to older age, certain racial/ethnic groups, lower income, and higher anti-spike antibody levels.

  • 5

    Vaccination and Asian race were associated with lower nucleocapsid reactivity, indicating complex interactions in immune response.

Original Source(s)

Demographic and Clinical Factors Associated With SARS-CoV-2 Anti-Nucleocapsid Antibody Response Among Previously Infected US Adults: The C4R Study

  • by Ryan T Demmer, Chaoqi Wu, John S Kim, Yifei Sun, Pallavi Balte, Mary Cushman, Rebekah Boyle, Russell P Tracy, Linda M Styer, Taison D Bell, Michaela R Anderson, Norrina B Allen, Pamela J Schreiner, Russell Bowler, David A Schwartz, Joyce S Lee, Vanessa Xanthakis, Jean M Rock, Rachel Bievenue, Amber Pirzada, Margaret Doyle, Elizabeth A Regan, Barry J Make, Alka M Kanaya, Namratha R Kandula, Sally E Wenzel, Josef Coresh, Carmen R Isasi, Laura M Raffield, Mitchell S V Elkind, Virginia J Howard, Victor E Ortega, Prescott Woodruff, Shelley A Cole, Joel M Henderson, Nicholas J Mantis, Elizabeth C Oelsner

  • March 20, 2025

Related Content

The latest developments on Ebola, hepatitis B, long Covid

Multi-omics analysis of long COVID (post-COVID-19 condition) reveals persistent mitochondrial dysfunction, suppressed oxidative phosphorylation, and immune dysregulation

“Who’s on Backup?”—Exploring Internal Medicine Residency Backup Coverage Systems: Findings from a National Survey